Aldeyra Therapeutics IncNASDAQ:ALDX
- LAST PRICE5.1833
- TODAY'S CHANGE (%)0.0033 (0.0637%)
- Bid / Lots5.1800/ 7
- Ask / Lots5.1900/ 7
- Open / Previous Close5.1200 / 5.1800
- Day Range
- 52 Week Range
- Volume179,072
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALDX |
|---|---|---|
| 09:32 ET | 9749 | 5.13 |
| 09:33 ET | 900 | 5.06 |
| 09:35 ET | 14250 | 4.97 |
| 09:37 ET | 6284 | 4.95 |
| 09:39 ET | 4864 | 4.9304 |
| 09:42 ET | 1617 | 4.96 |
| 09:44 ET | 2900 | 4.975 |
| 09:46 ET | 2773 | 5 |
| 09:48 ET | 5898 | 5.01 |
| 09:50 ET | 566 | 5 |
| 09:51 ET | 3077 | 5 |
| 09:53 ET | 1509 | 5.005 |
| 09:55 ET | 449 | 5.015 |
| 10:02 ET | 5494 | 5.01 |
| 10:04 ET | 11765 | 5.06 |
| 10:06 ET | 3700 | 5.08 |
| 10:08 ET | 100 | 5.07 |
| 10:09 ET | 400 | 5.08 |
| 10:11 ET | 1799 | 5.1 |
| 10:13 ET | 600 | 5.11 |
| 10:18 ET | 200 | 5.1 |
| 10:20 ET | 1826 | 5.08 |
| 10:22 ET | 300 | 5.065 |
| 10:24 ET | 5475 | 5.045 |
| 10:27 ET | 1358 | 5.07 |
| 10:29 ET | 11988 | 5.11 |
| 10:31 ET | 400 | 5.11 |
| 10:33 ET | 200 | 5.12 |
| 10:36 ET | 200 | 5.1 |
| 10:42 ET | 251 | 5.1 |
| 10:44 ET | 600 | 5.08 |
| 10:45 ET | 1817 | 5.13 |
| 10:47 ET | 7247 | 5.1699 |
| 10:49 ET | 196 | 5.17 |
| 10:51 ET | 100 | 5.18 |
| 11:02 ET | 300 | 5.1984 |
| 11:03 ET | 2061 | 5.19 |
| 11:05 ET | 100 | 5.195 |
| 11:07 ET | 2718 | 5.2199 |
| 11:12 ET | 927 | 5.18 |
| 11:23 ET | 6442 | 5.1915 |
| 11:25 ET | 400 | 5.19 |
| 11:34 ET | 900 | 5.19 |
| 11:36 ET | 4100 | 5.2 |
| 11:38 ET | 455 | 5.22 |
| 11:39 ET | 212 | 5.23 |
| 11:43 ET | 800 | 5.21 |
| 11:50 ET | 500 | 5.2 |
| 11:52 ET | 1200 | 5.21 |
| 11:54 ET | 1000 | 5.23 |
| 11:57 ET | 100 | 5.22 |
| 12:01 ET | 1636 | 5.21 |
| 12:03 ET | 121 | 5.21 |
| 12:08 ET | 300 | 5.19 |
| 12:10 ET | 20858 | 5.121 |
| 12:12 ET | 100 | 5.16 |
| 12:14 ET | 741 | 5.1833 |
Oct 31, 2024
Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting, from 7:00AM ET on Thursday Oct 31, 2024 by Dow Jones
7:00AM ET on Thursday Oct 31, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aldeyra Therapeutics Inc | 307.8M | -8.1x | --- |
Rezolute Inc | 304.2M | -4.1x | --- |
Design Therapeutics Inc | 301.2M | -6.1x | --- |
Compass Pathways PLC | 320.2M | -2.1x | --- |
Biomea Fusion Inc | 320.4M | -2.2x | --- |
Nautilus Biotechnology Inc | 322.7M | -4.7x | --- |
Company Information
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Contact Information
- Headquarters
- 131 HARTWELL AVENUE, SUITE 320LEXINGTON, MA, United States 02421
- Phone
- 781-761-4904
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Richard Douglas
- President, Chief Executive Officer, Director
- Todd Brady
- Principal Financial Officer and Principal Accounting Officer
- Michael Alfieri
- Chief Development Officer
- Stephen Machatha
- Independent Director
- Ben Bronstein
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $307.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 59.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.38 |
EPS | $-0.64 |
Book Value | $2.02 |
P/E Ratio | -8.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
